Optimizing Outcomes in Complement-Mediated Kidney Disease: Biomarkers, Emerging Therapies, and Collaborative Care

Complement-mediated kidney diseases (CMKDs), including C3 glomerulopathy, atypical hemolytic uremic syndrome, IgA nephropathy, and membranous nephropathy, are rare and complex disorders driven by dysregulation of the complement system and associated with poor renal outcomes. This online CME program provides nephrology clinicians and multidisciplinary kidney care professionals with an in-depth, practical framework for improving CMKD diagnosis and management through enhanced understanding of complement biology, biomarker-driven evaluation, histopathologic interpretation, and integration of newly approved and emerging targeted therapies. Using a blended digital learning model that combines self-paced education with expert-led interactive discussions and patient perspectives, the program emphasizes timely differential diagnosis, personalized treatment strategies, and collaborative care approaches to optimize patient outcomes and quality of life.